Could a shot every 2 months replace daily HIV pills for women?
NCT ID NCT03164564
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large phase 3 study tests whether a long-acting injectable drug called cabotegravir, given every 2 months, is safe and effective for preventing HIV in women. Over 3,200 HIV-negative women are taking part, comparing the shot to daily oral Truvada. The goal is to see if the injection offers a more convenient prevention option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabotegravir (long-acting injectable)
What this could lead to
If successful, this could provide women with a convenient, long-acting injection for HIV prevention, reducing the need for daily pills.
What could go wrong
This is a large phase 3 trial, but results are not yet final. The injection may not be as effective as daily pills for all women, and side effects like injection site reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor-Uganda CRS
Kampala, Uganda
-
Blantyre CRS
Blantyre, Malawi
-
Botha's Hill CRS
Durban, KwaZulu-Natal, 3660, South Africa
-
Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS
Cape Town, Western Cape, 7505, South Africa
-
Emavundleni CRS
Cape Town, Western Cape, 7750, South Africa
-
Eswatini Prevention Center CRS
Mbabane, Eswatini
-
Gaborone CRS
Gaborone, South-East District, Botswana
-
Isipingo CRS
Isipingo, KwaZulu-Natal, 4110, South Africa
-
Kisumu Crs
Kisumu, Nyanza, 40100, Kenya
-
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS
Kampala, Uganda
-
Malawi CRS
Lilongwe, Central Region, Malawi
-
Milton Park CRS
Harare, Zimbabwe
-
Seke South CRS
Chitungwiza, Zimbabwe
-
Soweto HPTN CRS
Johannesburg, Gauteng, 1862, South Africa
-
Spilhaus CRS
Harare, Zimbabwe
-
St Mary's CRS
Chitungwiza, Zimbabwe
-
UVRI-IAVI HIV Vaccine Program LTD. CRS
Entebbe, Uganda
-
Verulam CRS
Verulam, KwaZulu-Natal, 4340, South Africa
-
Ward 21 CRS
Johannesburg, Gauteng, 2001, South Africa
-
Zengeza CRS
Chitungwiza, Mashonaland East Province, Zimbabwe